1
|
Czekala L, Chapman F, Simms L, Rudd K, Trelles Sticken E, Wieczorek R, Bode LM, Pani J, Moelijker N, Derr R, Brandsma I, Hendriks G, Stevenson M, Walele T. The in vitro ToxTracker and Aneugen Clastogen Evaluation extension assay as a tool in the assessment of relative genotoxic potential of e-liquids and their aerosols. Mutagenesis 2021; 36:129-142. [PMID: 33769537 PMCID: PMC8166346 DOI: 10.1093/mutage/geaa033] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2020] [Accepted: 11/24/2020] [Indexed: 12/14/2022] Open
Abstract
In vitro (geno)toxicity assessment of electronic vapour products (EVPs), relative to conventional cigarette, currently uses assays, including the micronucleus and Ames tests. Whilst informative on induction of a finite endpoint and relative risk posed by test articles, such assays could benefit from mechanistic supplementation. The ToxTracker and Aneugen Clastogen Evaluation analysis can indicate the activation of reporters associated with (geno)toxicity, including DNA damage, oxidative stress, the p53-related stress response and protein damage. Here, we tested for the different effects of a selection of neat e-liquids, EVP aerosols and Kentucky reference 1R6F cigarette smoke samples in the ToxTracker assay. The assay was initially validated to assess whether a mixture of e-liquid base components, propylene glycol (PG) and vegetable glycerine (VG) had interfering effects within the system. This was achieved by spiking three positive controls into the system with neat PG/VG or phosphate-buffered saline bubbled (bPBS) PG/VG aerosol (nicotine and flavour free). PG/VG did not greatly affect responses induced by the compounds. Next, when compared to cigarette smoke samples, neat e-liquids and bPBS aerosols (tobacco flavour; 1.6% freebase nicotine, 1.6% nicotine salt or 0% nicotine) exhibited reduced and less complex responses. Tested up to a 10% concentration, EVP aerosol bPBS did not induce any ToxTracker reporters. Neat e-liquids, tested up to 1%, induced oxidative stress reporters, thought to be due to their effects on osmolarity in vitro. E-liquid nicotine content did not affect responses induced. Additionally, spiking nicotine alone only induced an oxidative stress response at a supraphysiological level. In conclusion, the ToxTracker assay is a quick, informative screen for genotoxic potential and mechanisms of a variety of (compositionally complex) samples, derived from cigarettes and EVPs. This assay has the potential for future application in the assessment battery for next-generation (smoking alternative) products, including EVPs.
Collapse
Affiliation(s)
- Lukasz Czekala
- Group Science and Regulatory Affairs, Imperial Brands PLC, Bristol, UK
| | - Fiona Chapman
- Group Science and Regulatory Affairs, Imperial Brands PLC, Bristol, UK
| | - Liam Simms
- Group Science and Regulatory Affairs, Imperial Brands PLC, Bristol, UK
| | - Kathryn Rudd
- Group Science and Regulatory Affairs, Imperial Brands PLC, Bristol, UK
| | - Edgar Trelles Sticken
- Reemtsma Cigarettenfabriken GmbH, an Imperial Brands PLC Company, Albert-Einstein-Ring-7, D-22761 Hamburg, Germany
| | - Roman Wieczorek
- Reemtsma Cigarettenfabriken GmbH, an Imperial Brands PLC Company, Albert-Einstein-Ring-7, D-22761 Hamburg, Germany
| | - Lisa Maria Bode
- Reemtsma Cigarettenfabriken GmbH, an Imperial Brands PLC Company, Albert-Einstein-Ring-7, D-22761 Hamburg, Germany
| | - Jutta Pani
- Reemtsma Cigarettenfabriken GmbH, an Imperial Brands PLC Company, Albert-Einstein-Ring-7, D-22761 Hamburg, Germany
| | - Nynke Moelijker
- Toxys B.V., Robert Boyleweg 4, 2333 CG Leiden, The Netherlands
| | - Remco Derr
- Toxys B.V., Robert Boyleweg 4, 2333 CG Leiden, The Netherlands
| | - Inger Brandsma
- Toxys B.V., Robert Boyleweg 4, 2333 CG Leiden, The Netherlands
| | - Giel Hendriks
- Toxys B.V., Robert Boyleweg 4, 2333 CG Leiden, The Netherlands
| | - Matthew Stevenson
- Group Science and Regulatory Affairs, Imperial Brands PLC, Bristol, UK
| | - Tanvir Walele
- Group Science and Regulatory Affairs, Imperial Brands PLC, Bristol, UK
| |
Collapse
|
2
|
Hawksworth A, Lockhart R, Crowe J, Maeso R, Ritter L, Dibben O, Bright H. Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness. Vaccine 2020; 38:4209-4218. [PMID: 32376111 DOI: 10.1016/j.vaccine.2020.04.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Revised: 12/17/2019] [Accepted: 04/01/2020] [Indexed: 12/24/2022]
Abstract
In the 2013-2014 and 2015-2016 influenza seasons, live attenuated influenza vaccine (LAIV) generated reduced vaccine effectiveness (VE) against circulating H1N1 strains. This reduced VE coincided with the introduction of pandemic 2009 H1N1 (A/H1N1pdm09) vaccine virus reassortants, in place of pre-2009 seasonal H1N1 strains. Here, we explored one specific hypothesis for reduced VE; decreased replicative fitness of A/H1N1pdm09 strains in humans. Two A/H1N1pdm09 strains with reduced VE, A/California/07/2009 (A/CA09) and A/Bolivia/559/2013 (A/BOL13), were compared to pre-2009 seasonal H1N1 strains, A/New Caledonia/20/1999 (A/NC99) and A/South Dakota/6/2007 (A/SD07). Initial results showed that A/H1N1pdm09 strains had reduced multi-cycle infectivity in Madin-Darby Canine Kidney (MDCK) cells, compared to their pre-2009 counterparts. The A/BOL13 viral titre was found to be 2.65 log10/mL lower when measured by multi-cycle 50% tissue culture infectious dose (TCID50) assay compared to single-cycle fluorescent focus assay (FFA). By contrast, clinically effective A/NC99 titres differed by only 0.54 log10/mL. In human alveolar (A549) cells, A/H1N1pdm09 strains replicated less than pre-2009 strains, with A/CA09 and A/BOL13 generating lower peak viral titres over 5 days. This phenotype was corroborated in physiologically relevant, primary human nasal epithelial cells (hNECs). Here, peak titres for pre-2009 strains A/NC99 and A/SD07 were 8.43 log10 TCID50/mL and 8.52 log10 TCID50/mL, respectively, versus 6.89 log10 TCID50/mL and 6.06 log10 TCID50/mL for A/H1N1pdm09 strains A/CA09 and A/BOL13. This confirmed a reduced ability of A/H1N1pdm09 strains to sustain replication in human respiratory cells. Using this information, H1N1 candidate A/Slovenia/2903/2015 (A/SLOV15) was characterised for replacement of A/BOL13 in the 2017/18 LAIV. A/SLOV15 produced comparable single and multi-cycle infectivity titres (Δ 0.16 log10/mL) and reached a peak titre 1.23 log10 TCID50/mL higher than that of A/BOL13 in hNEC cultures. Taken together, these data suggest a reduction in sustained multi-cycle replication in human cells as a plausible root cause for reduced A/H1N1pdm09 VE.
Collapse
|
3
|
Ferro MP, Leclerc L, Sleiman M, Marchiori B, Pourchez J, Owens RM, Ramuz M. Effect of E Cigarette Emissions on Tracheal Cells Monitored at the Air-Liquid Interface Using an Organic Electrochemical Transistor. ACTA ACUST UNITED AC 2018; 3:e1800249. [PMID: 32627404 DOI: 10.1002/adbi.201800249] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2018] [Revised: 11/22/2018] [Indexed: 11/10/2022]
Abstract
E-cigarettes have been suggested as a potentially healthier alternative to cigarettes based on studies using cell viability, DNA damage, and transcriptional response assays. However, little is known about the effect of e-cigarette aerosols on the integrity of the tracheal epithelium, specifically with respect to barrier resistance. This is partly due to the lack of methods for monitoring epithelia at the air-liquid interface (ALI), i.e., under physiological conditions. Here, it is shown that an organic electrochemical transistor can be adapted for the measurement of barrier resistance at the ALI. This technology enables accurate, continuous quantification of tracheal barrier integrity through the use of a conformable gate electrode placed on top of the cell-secreted mucus, obviating the need for addition of culture medium or buffer as a conductance medium for rigid electrodes. This platform allows for the detection of a dose-dependent, rapid decrease in barrier resistance of an in vitro model of human bronchial epithelium (MucilAir) after E-cigarette aerosols exposure. The system represents a powerful tool to study tissue responses of the human airway epithelium to inhaled smoke. The same technology will have broad applications for toxicology studies on other tissues with ALI, including other airway tissues and skin.
Collapse
Affiliation(s)
- Magali P Ferro
- Department of Bioelectronics, Mines Saint-Étienne, 880 route de Mimet, F-13541, Gardanne, France
| | - Lara Leclerc
- Department of Biomaterials and Inhaled Particles, Mines Saint-Étienne, Université Lyon, Université Jean Monnet, INSERM, U 1059 Sainbiose, Centre CIS, 158 cours Fauriel, F-42023, Saint-Étienne, France
| | - Mohamad Sleiman
- Department of Photochemical, Sigma Clermont, 27 Rue Roche Genès, 63178, Aubière, France
| | - Bastien Marchiori
- Department of Flexible Electronics, Mines Saint-Étienne, 880 route de Mimet, F-13541, Gardanne, France
| | - Jérémie Pourchez
- Department of Biomaterials and Inhaled Particles, Mines Saint-Étienne, Université Lyon, Université Jean Monnet, INSERM, U 1059 Sainbiose, Centre CIS, 158 cours Fauriel, F-42023, Saint-Étienne, France
| | - Roisin M Owens
- Department of Chemical Engineering and Biotechnology, Philippa Fawcett Drive, CB30AS, Cambridge, UK
| | - Marc Ramuz
- Department of Flexible Electronics, Mines Saint-Étienne, 880 route de Mimet, F-13541, Gardanne, France
| |
Collapse
|
4
|
Peitsch MC, Polosa R, Proctor C, Hassler T, Gaca M, Hill E, Hoeng J, Hayes AW. Next-generation tobacco and nicotine products. TOXICOLOGY RESEARCH AND APPLICATION 2018. [DOI: 10.1177/2397847318773701] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
A framework for the assessment of novel next-generation tobacco and nicotine products with the potential to reduce health risks compared with cigarettes should integrate scientific studies incorporating nonclinical, clinical, and population studies approaches. These products should have lower emissions and exhibit reduced biological effects compared with those of cigarettes, ideally approaching those of smoking cessation. The products should also be acceptable cigarette alternatives for current smokers, while not appealing to nonsmokers or former smokers. Validating harm reduction and promoting regulatory acceptance of the assessment methods require a collaborative approach by industry, independent reviewers, the public health community, and regulatory agencies. This article summarizes the science and approaches applied and considered to substantiate tobacco harm reduction in the light of regulatory requirements, presented at the 53rd Congress of the European Societies of Toxicology, 2017.
Collapse
Affiliation(s)
- Manuel C Peitsch
- Philip Morris International R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
| | - Riccardo Polosa
- Dipartimento di Medicina Clinica e Sperimentale, University of Catania, Catania, Italy
| | - Christopher Proctor
- British American Tobacco (Investments) Ltd., Group Research and Development, Southampton, UK
| | - Thord Hassler
- Swedish Match, European Division, Gothenburg, Sweden
| | - Marianna Gaca
- British American Tobacco (Investments) Ltd., Group Research and Development, Southampton, UK
| | - Erin Hill
- Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA
| | - Julia Hoeng
- Philip Morris International R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
| | - A Wallace Hayes
- Institute of Integrated Toxicology, Michigan State University, East Lansing, MI, USA
- College of Public Health, University of South Florida, Tampa, FL, USA
| |
Collapse
|